Aim of our study was to investigate effects of eptifibatide and anticoagulants on platelet aggregation and thrombin generation under low and high coagulant challenge in tissue factor-activated platelet rich plasma using a model allowing simultaneous determination of the time course of platelet aggregation and thrombin generation. Eptifibatide exerted a dose-dependent anti-aggregating effect under both high and significantly stronger under low coagulant challenge. Combination of eptifibatide and anticoagulants resulted in significant additive prolongation of the lag phase until the onset of platelet aggregation, more pronounced under low coagulant challenge. Under high, but not under low coagulant challenge combination of eptifibatide and anticoagulants had a significant synergistic inhibitory effect on platelet aggregation. Under low coagulant challenge combination of eptifibatide with LMWH, but not with UH, or rH, resulted in significantly reduced thrombin potential, F 1+2 generation, and FXa formation compared to measurements in the absence of eptifibatide. We demonstrate a synergistic effect of eptifibatide and anticoagulants on platelet aggregation inhibition and an additional inhibitory effect of LMWH and eptifibatide on thrombin generation. Our results support the notion that combination of eptifibatide and anticoagulants might be beneficial in atherosclerotic disease to palliate the thrombogenic potency of ruptured atherosclerotic plaques.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Treatment of cerebral venous thrombosis: a review.
Curr Med Res Opin
December 2024
The Aga Khan University, Neurology, Department of Medicine, Aga Khan University, Karachi, Pakistan.
Article Synopsis
- Cerebral venous thrombosis (CVT) is a rare type of stroke that may be linked to COVID-19 infection and vaccinations, with the management evolving to include fibrinolysis and mechanical thrombectomy.
- A literature review highlighted that low-molecular-weight heparin (LMWH) and unfractionated heparin (UH) are the recommended first-line treatments for acute CVT, while warfarin can be used later for prevention, although DOACs show promise as alternatives.
- Treatment approaches for COVID-19 related CVT are similar to non-COVID-19 CVT, but vaccine-related CVT requires different strategies involving non-heparin anticoagulants and possibly immunotherapy or steroids, emphasizing the
Adjunctive Intravenous Argatroban or Eptifibatide for Ischemic Stroke.
N Engl J Med
September 2024
From the Department of Emergency Medicine, Washington University, St. Louis (O.A., P.P., S.P.); the Departments of Neurology and Rehabilitation Medicine (J.B., I.D., S.D., M.H., P.K.), Emergency Medicine (A.P.), and Radiology (A.V.), University of Cincinnati, and the Department of Pharmacy, University of Cincinnati Medical Center (N.S.) - both in Cincinnati; the Department of Radiology, University of Virginia, Charlottesville (C.P.D.); the Clinical Institute for Research and Innovation, Memorial Hermann Hospital (J.C.G.), the Department of Neuroradiology, University of Texas M.D. Anderson Cancer Center (M.W.), and the Department of Neurology, University of Texas Health Science Center (A.D.B.), Houston, Berry Consultants, Austin (S.B., T.G.), and the Texas Stroke Institute, Medical City Healthcare, Dallas (A.J.Y.) - all in Texas; the Department of Emergency Medicine, University of Michigan, Ann Arbor (W.B.), and the Department of Neurology, McLaren Flint, Flint (A.M.) - both in Michigan; the Department of Neurology, University of Minnesota, Minneapolis (O.B., C.S.); the Department of Neurology, Sarasota Memorial Hospital, Intercoastal Medical Group, Sarasota (M.C.), and the Department of Neurology, Mayo Clinic, Jacksonville (J.H.) - both in Florida; the Department of Public Health Sciences, Medical University of South Carolina, Charleston (J.E., J.I.), and the Department of Medicine (Neurology), Prisma Health-Upstate, University of South Carolina Greenville School of Medicine, Greenville (S.S.); the Department of Emergency Medicine, Temple University, Philadelphia (N.G.); the National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD (S.J.); the Department of Neurology, Yale University, New Haven, CT (A.S.J.); the Departments of Neurology and Emergency Medicine, State University of New York, New York (S.R.L.); the Department of Neurology, Wake Forest University, Winston-Salem, NC (T.R.); and the Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom (A.W.).
Background: Intravenous thrombolysis is a standard treatment of acute ischemic stroke. The efficacy and safety of combining intravenous thrombolysis with argatroban (an anticoagulant agent) or eptifibatide (an antiplatelet agent) are unclear.
Methods: We conducted a phase 3, three-group, adaptive, single-blind, randomized, controlled clinical trial at 57 sites in the United States.
Article Synopsis
- A study analyzed 1,210 STEMI patients treated at a tertiary center from 2016 to 2022, revealing that the P2Y12 inhibitor ticagrelor significantly lowered all-cause and cardiovascular mortality, while GPI eptifibatide reduced cardiovascular mortality.
- Manual thrombus aspiration showed no significant impact on long-term survival, reinforcing the recommendation to avoid its routine use in STEMI treatment.
Thrombocytopenia is a rare but serious complication of the intravenous glycoprotein IIb/IIIa (GPIIb/IIIa; integrin αIIbβ3) receptor inhibitors (GPIs), abciximab, eptifibatide, and tirofiban. The thrombocytopenia ranges from mild (50 000-100 000 platelets/μL), to severe (20 000 to <50 000/μL), to profound (<20 000/μL). Profound thrombocytopenia appears to occur in <1% of patients receiving their first course of therapy.
View Article and Find Full Text PDFAn Updated Comprehensive Pharmacovigilance Study of Drug-Induced Thrombocytopenia Based on FDA Adverse Event Reporting System Data.
J Clin Pharmacol
April 2024
Department of Pharmacy, West China Hospital, Sichuan University, Chengdu, China.
Article Synopsis
- Drug-induced thrombocytopenia (DIT) is a significant health issue that has garnered attention due to its serious consequences and high prevalence, prompting a study analyzing data from the US FDA Adverse Event Reporting System (FAERS) from 2004 to 2022.
- The study found 168,657 DIT cases out of over 15 million reports and identified the top drugs involved, including lenalidomide and niraparib, ranked by the number of cases and signal strength.
- Additionally, the analysis highlighted that protein kinase inhibitors, antimetabolites, and monoclonal antibodies are the most affected drug groups, while some drug mechanisms behind DIT need further exploration.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!